[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 12, Issue 2 (summer 2012) ::
J Ardabil Univ Med Sci 2012, 12(2): 204-212 Back to browse issues page
Lutetium 177-Labeled Cetuximab Evaluation for Radioimmunotherapeutic Applications
Kamal Yavari *, Mohammad Ghannadi
Abstract:   (6586 Views)

  Background & Objectives: The monoclonal antibody cetuximab binds to EGFR and thus provides an opportunity to create both imaging and therapeutic modalities that target this receptor. The potential of cetuximab as a radioimmunoconjugate was investigated and quality control tests (in vitro and in vivo) were performed as a first step in the production of a new radiopharmaceutical.

  Methods : Cetuximab solution was dialyzed and concentrated using an Amicon Ultra-15 filter. Purified antibody was labeled with lutetium-177 using the acyclic bifunctional chelator, DOTA-NHS, and radioimmunoconjugates were purified by PD10 columns. Radiochemical purity and stability in buffer and human blood serum were determined using thin layer chromatography. Integrity of the radiolabeled complex was checked by SDS-PAGE. Preliminary biodistribution studies in normal mice model performed to determine radioimmunoconjugates distribution up to 72h.

  Results: The radiochemical purity of the complex was 98±1%. The stabilities in phosphate buffer and in human blood serum at 96 hours post-preparation were 96±2 % and 78±4%, respectively. All of the samples, controls and radiolabeled antibodies, showed a similar pattern of migration in the gel electrophoresis. Biodistribution of Lu177-cetuximab was evaluated in normal mice and the highest ID/g% was observed in the blood (13.2±1.3% at 24 hours) and the liver (9.1±1.3% at 24 hours).

  Conclusion: Our results show that DOTA-cituximab can be labeled with 177Lu. Lu177-cetuximab has sufficient stability and retains its integrity. The new complex could be considered for further evaluation in animals and possibly in humans as a new radiopharmaceutical for use in radioimmunotherapy of cancers.

Keywords: Cetuximab; Radioimmunotherapy; 177Lu; DOTA-NHS
Full-Text [PDF 384 kb]   (2037 Downloads)    
Type of Study: article | Subject: Special
Received: 2011/07/5 | Accepted: 2012/01/15 | Published: 2012/06/21
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Yavari K, Ghannadi M. Lutetium 177-Labeled Cetuximab Evaluation for Radioimmunotherapeutic Applications. J Ardabil Univ Med Sci. 2012; 12 (2) :204-212
URL: http://jarums.arums.ac.ir/article-1-143-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 12, Issue 2 (summer 2012) Back to browse issues page
مجله دانشگاه علوم پزشکی اردبیل Journal of Ardabil University of Medical Sciences
Persian site map - English site map - Created in 0.06 seconds with 30 queries by YEKTAWEB 4447